ArticleFrontiers in pharmacology2020

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.

Hong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.